- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07336199
Pairing Subjective Patient Rating and DBS Programming (PERCEPT-DBS)
Pairing Subjective Patient Rating and Local Field Potentials for DBS Programming
This multicenter, prospective and retrospective diagnostic study investigates personalized programming strategies for deep brain stimulation (DBS) in patients with Parkinson's disease. DBS of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease; however, optimization of stimulation parameters remains time-consuming and resource-intensive due to the growing complexity of electrode designs and programming options.
The PERCEPT-DBS study aims to improve DBS programming by combining subjective patient-reported outcomes with objective electrophysiological biomarkers. Specifically, the study examines the relationship between patients' subjective assessment of stimulation efficacy, measured using a visual analogue scale (VAS), and local field potentials (LFPs), with a focus on beta-band activity recorded from implanted DBS electrodes. These data are integrated with structural and functional neuroimaging to identify individualized stimulation "sweet spots" within the STN.
A total of 24 patients with idiopathic Parkinson's disease treated with bilateral STN-DBS will be recruited across several German DBS centers. Participants undergo standardized clinical assessments, VAS-based blinded monopolar reviews, and LFP recordings using sensing-enabled implantable pulse generators. In addition, imaging-based analyses are performed to relate electrophysiological and subjective measures to anatomical and connectomic features.
The primary objective is to determine whether electrophysiological markers correlate with subjective patient ratings and whether their overlap defines personalized optimal stimulation targets. By integrating patient perception with neurophysiological and imaging data, this study seeks to advance individualized DBS programming strategies and contribute to the development of more efficient, patient-centered, and potentially adaptive DBS therapies.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Thomas Köglsperger, PD Dr. med., MHBA
- Phone Number: +4989440073901
- Email: thomas.koeglsperger@med.uni-muenchen.de
Study Locations
-
-
-
München, Germany, 81377
- Recruiting
- LMU University Hospital
-
Contact:
- PD Dr. med. Thomas Köglsperger, MHBA
- Phone Number: 089440046433
- Email: thomas.koeglsperger@med.uni-muenchen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Age between 35 and 80 years
Clinically confirmed idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria
Status post bilateral deep brain stimulation of the subthalamic nucleus (STN-DBS)
Implanted DBS system suitable for electrophysiological recordings (prospective cohort: sensing-enabled IPG)
Ability to understand study procedures and communicate reliably with the investigator
Written informed consent provided
Exclusion Criteria:
Any condition impairing the ability to provide informed consent or comply with study procedures
Presence of exclusion criteria for Parkinson's disease according to MDS criteria
Manifest dementia according to ICD-10 criteria
Severe neurological, psychiatric, or medical conditions interfering with study participation or assessments
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Parkinson's disease patients with STN-DBS (PERCEPT-DBS cohort)
Patients with idiopathic Parkinson's disease who have undergone bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN).
Participants are implanted with sensing-enabled implantable pulse generators (e.g., Medtronic Percept™) and undergo standardized DBS programming assessments.
The intervention of interest includes DBS parameter testing combined with recording of local field potentials (LFPs) and patient-reported subjective ratings using a visual analogue scale (VAS).
Clinical assessments and neuroimaging data are integrated to identify personalized stimulation "sweet spots" and to evaluate the relationship between subjective symptom improvement and electrophysiological biomarkers.
|
No intervention (observational study)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between beta-band local field potentials and patient-reported DBS efficacy
Time Frame: 30 to 45 days after DBS electrode implantation (first study visit)
|
The primary outcome is the relationship between electrophysiological activity recorded from the subthalamic nucleus and subjective patient assessment of deep brain stimulation (DBS) efficacy.
Beta-band (13-30 Hz) local field potential (LFP) amplitude recorded from implanted DBS electrodes is correlated with patient-reported ratings of overall stimulation quality measured using a visual analogue scale (VAS) during blinded monopolar programming.
Outcome analyses assess whether electrophysiological markers correspond to higher subjective DBS benefit and whether overlapping signals define individualized stimulation "sweet spots."
|
30 to 45 days after DBS electrode implantation (first study visit)
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PERCEPT-DBS STUDY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease (PD)
-
University of Kansas Medical CenterNot yet recruitingParkinson's Disease (PD)United States
-
EicOsis Human Health Inc.University of California, Davis; Michael J. Fox Foundation for Parkinson's...RecruitingParkinson's Disease (PD)United States
-
University Hospital Schleswig-HolsteinUniversity of Kiel; University of Cologne; University Hospital, Bonn; Philipps...Not yet recruitingParkinson's Disease (PD)
-
Guangzhou Henovcom Bioscience Co. Ltd.Frontage Clinical Services, Inc.Active, not recruitingParkinson's Disease (PD)United States
-
Universitätsklinikum Hamburg-EppendorfUniversity of Oxford; University of TwenteRecruitingDeep Brain Stimulation | Parkinson's Disease (PD)Germany
-
Medical University of WarsawCompletedFull-Spectrum Cannabidiol Oil for Anxiety and Depressive Symptoms in Parkinson's Disease (COOPERATE)Parkinson's Disease (PD)Poland
-
Ege UniversityCompletedDysphagia | Parkinson's Disease (PD)Turkey (Türkiye)
-
University of FloridaCompletedParkinson Disease (PD)United States
-
Energenesis Biomedical Co., Ltd.Not yet recruitingParkinson's Disease (PD)Taiwan
-
Saglik Bilimleri UniversitesiEskisehir Osmangazi University; Anadolu UniversityRecruitingParkinson's Disease (PD)Turkey (Türkiye)
Clinical Trials on No intervention (observational study)
-
Drexel UniversityCompletedOsteoporosisUnited States
-
The Aurum Institute NPCKarolinska Institutet; Ludwig-Maximilians - University of Munich; University... and other collaboratorsUnknownRespiratory Tract Infections | Tuberculosis, PulmonaryMozambique, South Africa, Tanzania, Gambia
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
University Hospital, Basel, SwitzerlandCompletedPostoperative Complications | Intraoperative Complications | Patient Safety | Risk ManagementNew Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
-
Hôpital Necker-Enfants MaladesUnknown
-
University Health Network, TorontoNot yet recruitingCardiac Surgery Requiring Cardiopulmonary Bypass
-
Gulbenkian Institute for Molecular MedicineCUF Tejo Hospital; Hospital CUF Descobertas, Lisbon, Portugal; Hospital da Luz...RecruitingMicrobiome | Colorectal Cancer Screening | Colorectal Cancer (CRC)Portugal
-
The First Affiliated Hospital of Xinxiang Medical...Anyang Cancer Hospital; Xinxiang Central Hospital of Henan province; Inner Huang... and other collaboratorsNot yet recruiting
-
Liverpool School of Tropical MedicineLondon School of Hygiene and Tropical Medicine; Wellcome Trust; University of... and other collaboratorsRecruitingKidney Diseases | Chronic Kidney Diseases | Non-communicable Disease | Non-Communicable Chronic DiseasesMalawi
-
Nanfang Hospital of Southern Medical UniversityThe First Affiliated Hospital of Anhui Medical University; Xiangya Hospital... and other collaboratorsRecruiting